Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

This Month in Gastroenterology

(2010) Jan Tack et al.   GASTROENTEROLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes and the CDAI

(2009) Alain M Schoepfer et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Biological Therapies for Inflammatory Bowel Diseases

(2009) Paul Rutgeerts et al.   GASTROENTEROLOGY

A fat chance for hepatocyte transplantation?

(2009) J. A Thomas et al.   GUT

Tailoring the length of antiviral treatment for hepatitis C

(2009) A. Mangia et al.   GUT

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohnʼs disease

(2009) Geert R. DʼHaens et al.   INFLAMMATORY BOWEL DISEASES

Ulcerative colitis

(2009) Alain M. Schoepfer et al.   INFLAMMATORY BOWEL DISEASES

Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment

(2009) Taina Sipponen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohnʼs disease

(2008) Taina Sipponen et al.   INFLAMMATORY BOWEL DISEASES